High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

ECOG-ACRIN Cancer Research Group

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Brief summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status
COMPLETED
phase
PHASE3
study type
INTERVENTIONAL
enrollment
1150
sponsor
ECOG-ACRIN Cancer Research Group
conditions
Melanoma (Skin)
interventions
BIOLOGICAL: interferon alfa-2b; OTHER: observation
start date
1999-03-25
start date type
ACTUAL
primary completion date
2015-01-01
has results
true
data source
ClinicalTrials.gov
data processed
2026-10-29T09:00:05
modifications
selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Record

Archive ID
nct:NCT00003641
Published
Jan 27, 2003
Updated
Sep 29, 2026
Venue
ClinicalTrials.gov
ClinicalTrials.gov
NCT00003641
Categories
Melanoma (Skin)
License
ClinicalTrials.gov terms (attribution, processing date, modifications noted)
Provenance
clinicaltrials

Topics